Singapore -based Hilleman Laboratories, along with Bharat Biotech, confirm launch of new cholera vaccine, HILLCHOL® Success provides "template for the internationalization of future vaccine and biologics development from Singapore " – Dr. Raman Rao , CEO, Hilleman Laboratories Hilleman Laboratories Singapore hub advancing global health equity by developing portfolio of vaccines that could benefit up to 500 million people in low- and middle-income countries Announcement marks significant public health milestone towards pre-qualification from the WHO for wider distribution globally SINGAPORE , Aug. 27, 2024 /PRNewswire/ -- Hilleman Laboratories has today announced that its partner Bharat Biotech, has successfully launched HILLCHOL®, a breakthrough oral cholera vaccine (OCV), achieving a significant global public health milestone.
Singapore -based Hilleman Laboratories - a joint venture between MSD and Wellcome - is a first-of-its-kind vaccine development hub, focused on accelerated end-to-end research and the development of affordable vaccines for distribution in low- and middle-income countries (LMICs). The launch of HILLCHOL® is a result of an innovative model of international partnership between Hilleman Laboratories and Bharat Biotech, an Indian multinational biotechnology company. Today's announcement follows the successful completion of HILLCHOL® Phase III clinical trials and approval for licensure by Bharat Biotech in India .
This is after Hilleman Laboratories dev.